Data on Protalix's (PLX) ELELYSO to be Presented at 10th Annual European Working Group on Gaucher Disease Meeting
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Join SI Premium – FREE
Protalix BioTherapeutics, Inc. (NYSE: PLX) announced today that new clinical data on ELELYSO™ will be presented at the 10th Annual European Working Group on Gaucher Disease Meeting being held June 28-30 in Paris, France, at the Novotel Paris Tour Eiffel Convention Center.
Laura van Dussen, M.D., Researcher at the Academic Medical Center in Amsterdam, is scheduled to deliver an oral presentation entitled "Taliglucerase alfa Leads to Favorable Bone Marrow Responses in Patients with Type 1 Gaucher Disease," on Friday, June 29 at 9:45 AM CEST.
Gregory Pastores, M.D., Professor of Neurology and Pediatrics and Director of the Neurogenetics Laboratory at New York University School of Medicine, is scheduled to deliver an oral presentation entitled "Plant-Cell-Expressed Recombinant Glucocerebrosidase - taliglucerase alfa as Therapy for Gaucher Disease," on Saturday, June 30 at 10:45 AM CEST.
Professor Ari Zimran, M.D., Director of the Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem, Israel, is scheduled to deliver an oral presentation entitled "A Multicenter, Double-Blind, Randomized Safety and Efficacy Study of Two Dose Levels of taliglucerase alfa in Pediatric Subjects with Gaucher Disease," on Saturday, June 30 at 11:00 AM CEST.
In addition to the oral presentation at the conference, Raul Chertkoff, M.D., the Company's Vice President of Medical Affairs, will introduce a poster entitled "Comparative Analysis of Taliglucerase Alfa Efficacy Response with Enzyme Replacement Therapies for Gaucher Disease." Dr. Pastores will introduce a poster entitled "Evaluation of Taliglucerase Alfa Efficacy Respective to Therapeutic Goals." Pamela Becker, M.D., Ph.D., will introduce a poster entitled "Efficacy of Taliglucerase Alfa, Imiglucerase, and Velaglucerase Alfa: A Comparative Analysis of Published Clinical Studies." Last, Luc Bracoud will introduce a poster entitled "Variability assessment of spleen volume measurements based on MRI sequence selection in Gaucher subjects."
Laura van Dussen, M.D., Researcher at the Academic Medical Center in Amsterdam, is scheduled to deliver an oral presentation entitled "Taliglucerase alfa Leads to Favorable Bone Marrow Responses in Patients with Type 1 Gaucher Disease," on Friday, June 29 at 9:45 AM CEST.
Gregory Pastores, M.D., Professor of Neurology and Pediatrics and Director of the Neurogenetics Laboratory at New York University School of Medicine, is scheduled to deliver an oral presentation entitled "Plant-Cell-Expressed Recombinant Glucocerebrosidase - taliglucerase alfa as Therapy for Gaucher Disease," on Saturday, June 30 at 10:45 AM CEST.
Professor Ari Zimran, M.D., Director of the Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem, Israel, is scheduled to deliver an oral presentation entitled "A Multicenter, Double-Blind, Randomized Safety and Efficacy Study of Two Dose Levels of taliglucerase alfa in Pediatric Subjects with Gaucher Disease," on Saturday, June 30 at 11:00 AM CEST.
In addition to the oral presentation at the conference, Raul Chertkoff, M.D., the Company's Vice President of Medical Affairs, will introduce a poster entitled "Comparative Analysis of Taliglucerase Alfa Efficacy Response with Enzyme Replacement Therapies for Gaucher Disease." Dr. Pastores will introduce a poster entitled "Evaluation of Taliglucerase Alfa Efficacy Respective to Therapeutic Goals." Pamela Becker, M.D., Ph.D., will introduce a poster entitled "Efficacy of Taliglucerase Alfa, Imiglucerase, and Velaglucerase Alfa: A Comparative Analysis of Published Clinical Studies." Last, Luc Bracoud will introduce a poster entitled "Variability assessment of spleen volume measurements based on MRI sequence selection in Gaucher subjects."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Take-Two Interactive Software (TTWO) to Cut 5% Staff, Announces Cost Reduction Plan
- CareDx (CDNA) Appoints John W. Hanna as CEO
- Toronto-Dominion Bank (TD) Appoints Matt Boss as Head of U.S. Consumer Banking
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
